Despite much progress in treatment options in the last century, the pharmacological treatment of psychotic disorders is often unsatisfactory, as expressed in persistent positive, negative, cognitive and affective symptoms, and problems in social functioning ([@bib81]). Psychotic symptoms are often only partially resolved ([@bib135]), especially cognitive and negative symptoms ([@bib18]). Apart from clozapine, second-generation antipsychotics are generally as effective as first-generation antipsychotics for positive symptoms, but the promise of greater efficacy for negative symptoms has not been fulfilled ([@bib102]). Many patients continue experiencing persistent symptoms and relapses during treatment with antipsychotics, particularly when they fail to adhere to prescribed medications ([@bib164]). Psychiatric medication adherence is a problem because many patients do not want them or consider them unnecessary ([@bib25]), or experience undesired adverse effects ([@bib120]). For antipsychotics, these adverse effects include weight gain, sexual dysfunction, glycemic and lipid dysfunction, extrapyramidal symptoms (EPS), and sedation ([@bib145]).

Many patients with psychotic disorders use nonconventional medicines or treatments in the hope of decreasing undesired adverse effects or a more successful recovery ([@bib60]; [@bib146]). Nonconventional medicine includes therapeutic lifestyle changes and complementary and alternative medicine (CAM) ([@bib70]). Complementary medicine comprises diagnostics, treatments, and prevention strategies based on theories accepted in biomedicine and substantiated by some scientific evidence (two or more randomized controlled trials \[RCTs\]), but for various (cultural or practical) reasons are no part of biomedicine ([@bib69]). Alternative medicine comprises diagnostics, treatments, and prevention strategies using other than the basic concepts of biomedicine. So far, there is little proof for the efficacy of the latter treatments and/or considerable controversy about their scientific validation ([@bib91]). Natural medicine is part of complementary medicine, using agents produced by living organisms (plant, tree, seed, vegetable, fruit, animal, and human) instead of nonnatural (*i.e.*, chemical) agents only being obtained from laboratory experiments ([@bib126]). Some patients prefer natural medicines, assuming that natural is better and will cause fewer adverse effects. This is obviously not (always) true, as the natural environment contains agents that can be toxic to humans. The molecular structure and dosage of a substance rather than its source determine its effect on human health ([@bib153]). Besides, herbal medicines can cause undesired effects including interactions with prescription medication ([@bib44], [@bib45]).

[@bib60] reported a lifetime and 1-year prevalence rate of CAM use in Canadian psychotic outpatients of 88% and 68%, respectively. A major difficulty these patients encounter is the heterogeneity in treatment options with CAM, ranging from possibly interesting agents to useless, or even dangerous, ones ([@bib45]). For instance, the concomitant use of antipsychotics and Chinese herbs was found to induce significantly improved clinical outcomes compared with antipsychotics only ([@bib130]). However, a small but significant number of patients concomitantly treated with Chinese herbs have a greater risk of developing worse outcomes ([@bib180]).

In recent years, patients\' preferences and views have received more attention in making treatment choices (*e.g.*, shared decision making \[[@bib39]\] and "patient-centered care" \[[@bib51]\]). The introduction of patient\'s choice in deciding which antipsychotic to choose has been proposed ([@bib115]). However, it is difficult for both patients and physicians to make informed decisions in the absence of reliable information on the emerging evidence for CAM or natural medicine. Considering its high usage in psychotic patients, there is an urgent need for readily available scientific information.

This article reviews the literature on the efficacy and safety of natural medicines for psychotic disorders.

REVIEW
======

Materials and Methods
---------------------

### Literature Search and Study Selection

Studies were identified by a literature search in Medline, PsycINFO, CINAHL, and Cochrane, until May 2015, in accordance with the Medline RCT filter. The search terms (MeSH Thesaurus and free search terms) used were schizophrenia, psychosis, psychoses, psychotic (disorder), schizophreniform AND (R)CT, review AND complementary medicines, herbs, vitamins, supplements (search terms, in alphabetical order: alpha lipoic acid \[ALA\], artemisinin, ascorbic acid, Ayurveda, brahmyadiyoga, branched-chain amino acids \[BCAA\], Chinese herbs, [d]{.smallcaps}-cycloserine, [d]{.smallcaps}-serine, daotan decoction, dehydroepiandrosterone \[DHEA\], docosahexaenoic acid \[DHA\], eicosapentaenoic acid \[EPA\], estradiol, fatty acid, fish oil, folic acid, ginkgo biloba, glycine, jiawei lingguizhugan tang, jieyu anshen decoction, [l]{.smallcaps}-stepholidine, [l]{.smallcaps}-theanine, manganese, methylfolate, *N*-acetylcysteine \[NAC\], *N*-methylglycine, niacine, omega-3, orengedokuto, rauwolfia serpentina, saikokaryukotsuboreito, sarcosine, sarsasapogenin, selenium, shakuyakukanzoto, shuizhi dahuang mixture, suo quan, tongdatang serial recipe \[TDT\], traditional Chinese medicine \[TCM\], vitamin B complex, vitamin B3, vitamin C, vitamin D, vitamin E, and zinc). After systematic deduplication, 1465 hits (abstracts) were retrieved (Table [1](#T1){ref-type="table"}).
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Next, abstracts about the following topics were included: a) effects of natural medicines on psychotic symptoms in schizophrenia spectrum nonaffective disorders and b) effects of natural medicines on the adverse effects of antipsychotics. Those excluded were a) nonrandomized (controlled) trials; b) mechanism studies exploring the effects of natural medicines; c) animal studies; d) affective disorders/other disorders/no disorder/(relapse) prevention; e) conference abstracts; f) book chapters; g) clinical trial registrations; h) comments, addenda, corrigenda, and letters; i) non-English languages (*e.g.*, Chinese, Japanese, Hebrew, German, and Spanish); and (j) duplicate hits that had not been removed systematically. Second, two authors (H.J.R.H. and A.A.B.V.) independently indicated whether papers---based on the abstracts---should (possibly) be included. Consultation followed about dubious cases and in case of discordance. Thereupon, 427 studies remained, of which the full papers on RCTs were retrieved and studied. Of these, another 160 were excluded. A flowchart of the study selection is presented in Figure [1](#F1){ref-type="fig"}. We found 147 reviews and checked whether RCTs in their reference lists matching our inclusion criteria were included. Eight RCTs with a Jadad score of 3 or higher (see paragraph on risk of bias assessment and Table [2](#T2){ref-type="table"}) found through cross-references were added. Eighteen RCTs were excluded because of a Jadad score less than 3. The reviews (not shown in Table [3](#T3){ref-type="table"}) will be contrasted to our findings in the Discussion section.

![Flowchart of study selection.](nmd-206-81-g002){#F1}
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Jadad Scale for Assessing the Quality of RCTs
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###### 

Overview of Effects of Natural Medicines for Psychotic Disorders
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### Classification of Agents

The RCTs included were divided into six groups based on supposed underlying mechanisms of action (Table [3](#T3){ref-type="table"}). For a good grasp of the results, we briefly present the working mechanisms of the agents from five groups (not from the group "other substances").

\(i\) Omega-3 fatty acids. Polyunsaturated fatty acids (PUFAs) are essential for brain functioning ([@bib159]). They have multiple important biological roles, including membrane functioning, neurotransmission, signal transduction, and eicosanoid synthesis. Research suggests that PUFA level reduction is related to schizophrenia ([@bib13]). Concordant with these findings, omega-3 PUFA may have positive effects in the treatment of schizophrenia ([@bib40]; [@bib122]).

\(ii\) Glutamate. Besides dopamine, glutamate is thought to play a role in schizophrenia ([@bib156]). On the basis of the hypothesis that the glutamatergic system may be compromised in schizophrenia, the use of *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor modulators may compensate for alterations in the glutamate system ([@bib142]). Agents with coagonistic properties to (glutaminergic) NMDA receptors are glycine (full, endogenous agonist), [d]{.smallcaps}-serine (full, endogenous agonist), [d]{.smallcaps}-cycloserine (partial, exogenous agonist), [d]{.smallcaps}-alanine (partial, endogenous agonist), and sarcosine (= methylglycine, acting as a reuptake inhibitor of glycine and source of glycine). The glycine transporter-1 (GlyT-1) plays a pivotal role in maintaining the glycine concentration within synapses at a subsaturating level. Sarcosine is a GlyT-1 inhibitor, meaning that its presence results in increased glycine concentrations. Lower cerebral glycine levels are suggested to be found in patients with schizophrenia. The administration of sarcosine is therefore proposed to relieve symptoms of schizophrenia when added to nonclozapine antipsychotics ([@bib94]). Whereas the mechanisms of NAC are now beginning to be understood, NAC is probably exerting benefits beyond being a precursor to the antioxidant glutathione, also modulating glutamatergic, neurotropic, and inflammatory pathways ([@bib28]).

\(iii\) Eastern (Chinese and ayurvedic) herbs. Eastern herbs are provided in the context of treatment with complete systems of medicine that evolved over thousands of years, such as TCM and Ayurveda. These treatments include prescription of herbal compounds, massage, diet, acupuncture, and the regulation of lifestyle ([@bib24]; [@bib82]). Most clinical studies were performed on acupuncture (beyond the scope of this review) and on herbal compounds.

\(iv\) B vitamins. Nobel laureate Linus Pauling proposed a way of understanding and treating psychiatric disorders by correcting malfunctions in the body\'s chemistry, calling this approach "orthomolecular psychiatry" ([@bib121]). His idea was partly built on studies by [@bib119] and [@bib73], reporting good results when treating patients with schizophrenia with large doses of vitamins, especially vitamin B3. [@bib71], [@bib72] published two more positive results with B vitamins. However, attempts to replicate his findings seem to have failed ([@bib10]; [@bib171]). The contradicting findings may be explained because vitamine B is suggested to be effective in early psychosis but not in chronic schizophrenia ([@bib73]). One of the proposed mechanisms is abnormal one-carbon metabolism due to vitamin deficiencies ([@bib74]). Variable levels of the components of one-carbon metabolism (folic acid \[= vitamin B9\] and vitamin B12) and consequently altered levels of homocysteine and phospholipid DHA have been reported both in medicated patients and in medication-naive first-episode psychotic patients ([@bib80]). Folate status in patients with schizophrenia correlates inversely with negative symptoms ([@bib54]).

\(v\) Antioxidants. Oxygen is essential in life but also generates reactive molecules (so-called free radicals) throughout the body. These free radicals are potentially harmful because they can damage essential molecules such as DNA and the enzymes necessary for proper cell functioning. Antioxidants may capture these reactive free radicals and convert them back to less reactive forms of the molecules ([@bib143]). Research suggests that oxidative damage (maybe due to defective enzyme systems) may contribute to the course and outcome of schizophrenia ([@bib47]; [@bib109]; [@bib108]) and is already present in patients with first-episode psychosis ([@bib49]).

Ascorbic acid (vitamin C), an antioxidant vitamin, plays an important role in protecting free radical-induced damage in the body. It is present in brain tissue and dopamine-dominant areas in higher concentrations compared with other organs ([@bib59]). Ginkgo biloba, an extract of the leaves of the ginkgo biloba tree, is also suggested to have antioxidant properties ([@bib107]), improving brain circulation at the microvascular level ([@bib87]; [@bib149]; [@bib174]) and, thus, improving outcome in psychosis.

Long-term treatment with antipsychotics is associated with a variety of movement disorders, including tardive dyskinesia (TD). Both dopamine receptor supersensitivity and oxidative stress-induced neurotoxicity in the nigrostriatal system are suggested to be involved in its pathogenesis ([@bib90]). The pineal hormone melatonin is a potent antioxidant and attenuates dopaminergic activity in the striatum and dopamine release from the hypothalamus ([@bib140]). Thus, treatment with antioxidative agents may have a beneficial effect for both treatment of psychotic symptoms and prevention of TD. Vitamin E has been suggested for TD because it is a lipid-soluble antioxidant that decreases free radical formation ([@bib66]).

### Risk of Bias Assessment

Two assessors (A.A.B.V. and N.K.V.) independently rated the methodological quality of the eligible RCTs using the Jadad scale ([@bib76]). Interrater agreement on the Jadad scores before consensus discussion amounted to 0.83. Besides, H.J.R.H. independently rated a random selection of 17 papers (15%) from the selected RCTs. Interrater agreement of all three assessors was 0.71. Any scoring disagreements between the assessors were resolved through consensus discussion between these three authors. The 110 RCTs with a Jadad score of 3 or higher were included in the current review, categorized into six groups (see the Classification of agents section).

For each of the 110 studies fulfilling the selection criteria, the following assessments were made: which natural agent was used; was this combined with antipsychotics, and if so, which antipsychotics and what dosage; the effect of the natural agent on negative, positive, cognitive, depressive, and general symptoms and on adverse effects of antipsychotics; possible adverse effects of the natural agent; number of participants in the study; control group characteristics; number of dropouts; study duration; and Jadad score. The results are shown in Table [3](#T3){ref-type="table"}.

Results
-------

In total, 110 RCTs that matched the inclusion criteria were identified. Detailed effects are given in Table [3](#T3){ref-type="table"}. Most of the studies were performed in the United States, followed by (in decreasing order) Israel, Canada, Taiwan, China, India, United Kingdom, Australia, Iran, South Africa, Switzerland, the Netherlands, Austria, Ireland, Korea, and Norway.

### (i) Omega-3 Fatty Acids

Eleven RCTs on omega-3 were included ([@bib11]; [@bib12]; [@bib40], [@bib41], [@bib42]; [@bib48]; [@bib111]; [@bib123]; [@bib124]; [@bib152]; [@bib161]), and one combined omega-3 with vitamins E and C ([@bib11]). In studies combining antipsychotics with omega-3 PUFA, one (from five) study on negative symptoms in schizophrenia found some positive effect (in patients using clozapine; [@bib124]), two (from four) found some positive effect on positive symptoms ([@bib123]; [@bib124]; one only in patients using clozapine \[[@bib124]\]), one (from two) on cognitive symptoms ([@bib161]), none (from three) on depressive symptoms, and four (from eight) on general psychopathology ([@bib40]; [@bib123]; [@bib124]; [@bib161]; one only in patients using clozapine \[[@bib124]\]). One (from one) study on omega-3 PUFA without antipsychotics reported a decrease of positive symptoms ([@bib123]). Three (from six) reported less adverse effects of antipsychotics (EPS and/or dyskinesia) ([@bib12]; [@bib40]; [@bib161]). Two studies reported less use of antipsychotics in the omega-3 PUFA group ([@bib12]; [@bib123]). One study reported an increase in positive symptoms by omega-3 (EPA), but only among those with low levels of red blood cell PUFA. This effect disappeared when EPA was combined with vitamin E and vitamin C ([@bib11]). Some nonsevere adverse effects of omega-3 PUFA were reported, such as mild gastrointestinal problems and increased bleeding time.

### (ii) Glutamate

Nine RCTs on glycine ([@bib17]; [@bib30]; [@bib46]; [@bib62], [@bib61]; [@bib65]; [@bib78], [@bib77]; [@bib127]), eight on [d]{.smallcaps}-serine ([@bib34]; [@bib43]; [@bib64]; [@bib93], [@bib95]; [@bib155], [@bib158]; [@bib169]), ten on [d]{.smallcaps}-cycloserine ([@bib17]; [@bib19]; [@bib35]; [@bib54], [@bib53]; [@bib55]; [@bib63]; [@bib134]; [@bib162]; [@bib175]), one on [d]{.smallcaps}-alanine ([@bib157]), five on sarcosine ([@bib93], [@bib94], [@bib95], [@bib96]; [@bib154]), and two on NAC ([@bib14]; [@bib97]) were included.

Glycine improved negative symptoms when combined with antipsychotics in six (from seven) studies ([@bib17]; [@bib62], [@bib61]; [@bib65]; [@bib78], [@bib77]), but not when combined with clozapine (two studies) ([@bib127]; [@bib46]). Positive symptoms improved in one study ([@bib61]), worsened in another (with clozapine) ([@bib127]), and did not change in five (from seven) studies ([@bib30]; [@bib46]; [@bib62]; [@bib65]; [@bib78]); cognitive improvement was shown in four ([@bib62], [@bib61]; [@bib65]; [@bib61]; [@bib77]) and no change in two (from seven) studies ([@bib17]; [@bib46]); depressive symptoms diminished in four (from four) studies ([@bib62], [@bib61]; [@bib65]; [@bib77]); and improvement of general psychopathology was shown in three (from eight) studies ([@bib62], [@bib61]; [@bib65]). No adverse effects of glycine were reported, except some mild gastrointestinal complaints.

[d]{.smallcaps}-Serine was shown to improve positive, negative, and cognitive symptoms and general psychopathology in two (from six) studies when added to antipsychotics ([@bib64]; [@bib155]). The three largest studies with the highest Jadad score did not show a significant effect of [d]{.smallcaps}-serine on any symptom ([@bib93]; [@bib95]; [@bib169]). In four (from six) studies, [d]{.smallcaps}-serine did not improve adverse effects of antipsychotics ([@bib93], [@bib95]; [@bib155], [@bib158]). Insomnia, weight gain, palpitations, and other adverse effects of [d]{.smallcaps}-serine were reported. One study found improvement by [d]{.smallcaps}-serine without antipsychotics, but this was significantly less compared with the improvement in the olanzapine group; D-serine, however, caused less adverse effects ([@bib43]).

[d]{.smallcaps}-Cycloserine showed an improvement of negative symptoms in three (from nine) studies when added to antipsychotics ([@bib53]; [@bib63]; [@bib175]); some improvement of positive symptoms in one ([@bib55]) and worsening in another study (from seven) ([@bib162]); and little or no effect on cognitive and depressive symptoms or general psychopathology and no improvement of adverse effects of antipsychotics was shown. Five (from five) studies found no improvement of adverse effects of antipsychotics ([@bib17]; [@bib35]; [@bib54]; [@bib63]; [@bib162]). No studies were reported on [d]{.smallcaps}-cycloserine without antipsychotics. No adverse effects of [d]{.smallcaps}-cycloserine were reported.

The only study on [d]{.smallcaps}-alanine reported positive effects when added to antipsychotics on negative, positive, cognitive, and general symptoms, but no effect on depressive symptoms ([@bib157]). No effect on adverse effects of antipsychotics was found. Adverse effects of [d]{.smallcaps}-alanine (insomnia and nausea) were reported.

All three studies combining sarcosine with antipsychotics (not clozapine) found positive effects in almost all symptom domains ([@bib93], [@bib95]; [@bib154]). When combined with clozapine (one study), no treatment effects were found ([@bib94]). In addition, when given without antipsychotics (one study), sarcosine did not improve symptoms ([@bib96]). Sarcosine did not improve adverse effects of antipsychotics in four (from four) studies ([@bib93], [@bib94], [@bib95]; [@bib154]). Adverse effects of sarcosine included weight gain, insomnia, palpitations, dizziness, and sedation.

One large study on NAC added to antipsychotics reported improved positive symptoms but no improvement of negative, cognitive, or general symptoms and no improvement of adverse effects of antipsychotics ([@bib14]), whereas one small study found some improvement of cognitive symptoms ([@bib97]). The large study ([@bib14]) reported that there were no adverse effects, and in the small study ([@bib97]), occurrence of any adverse effect was not mentioned.

### (iii) Eastern (Chinese and Ayurvedic) Herbs

Many studies on Eastern herbs were found, but only six had a Jadad score of three or higher ([@bib20], [@bib21], [@bib22]; [@bib110]; [@bib116]; [@bib118]). One old study on reserpine found "clinical improvement" after 11 weeks compared with placebo in 80 patients not treated with antipsychotics but with electroconvulsice therapy ([@bib118]). Several adverse effects were reported: nasal congestion, periorbital edema, diarrhea, epigastric pain, salivating, pseudo-Parkinsonian state, severe headaches, and deep pains in limbs. Another old study ([@bib110]) found positive effects of brahmyadiyoga without antipsychotics compared with placebo and equal to chlorpromazin in 136 patients with schizophrenia ([@bib110]); no adverse effects were reported. Four (from six) more recent studies found significant effects on general psychopathology when adding ayurvedic herbs (reserpine: one study \[[@bib118]\]; bacopa monnieri and nardostachys jatamansi: one study \[[@bib116]\]; a mixture of 13 Chinese herbs: two studies \[[@bib20], [@bib21], [@bib22]\]) to antipsychotics.

The ayurvedic herbs were compared with 10 mg of olanzapine in a 76-week noninferiority study in 200 patients. No statistically significant differences were found between both groups examining improvement of positive and negative symptoms and general psychopathology. The ayurvedic group had less weight gain ([@bib116]). Two large studies by [@bib20], [@bib21], [@bib22] of a mixture of 13 Chinese herbs found an improvement on general psychopathology. When kidney yang was added to risperidone, an improvement on cognitive and depressive symptoms was found in one study (from two) ([@bib20], [@bib22]). One study found no effect of the Chinese herb sarsasapogenin compared with placebo when added to risperidone on positive, negative, and cognitive symptoms or general psychopathology in 90 patients during 8 weeks ([@bib173]). Many different nonsevere adverse effects were reported (*e.g.*, gastrointestinal, drowsiness, and insomnia).

### (iv) B Vitamins

Nineteen RCTs on B vitamins added to antipsychotics ([@bib8], [@bib7]; [@bib29]; [@bib52]; [@bib67]; [@bib79]; [@bib84]; [@bib101], [@bib100], [@bib98], [@bib99]; [@bib104]; [@bib112]; [@bib113]; [@bib114]; [@bib125]; [@bib129]; [@bib133]; [@bib136]; [@bib170]) and one on B3 without antipsychotics ([@bib57]) were found. B1 showed some positive effect on general psychopathology (when combined with B6 and B12) in one study ([@bib79]) and on positive and negative symptoms in another ([@bib136]). B3 showed improved general psychopathology in three (from nine) studies ([@bib8], [@bib7]; [@bib125]). B6 improved general psychopathology in four (from five) studies ([@bib7]; [@bib98]; [@bib114]; [@bib125]). In one study, general psychopathology improved after the administration of methylfolate ([@bib52]). One study reported no effect of B9 (folic acid) ([@bib67]). Another study showed a positive effect of combined B6, B9, and B12 on positive, negative, and cognitive symptoms ([@bib104]). Yet, another study showed improved negative symptoms by adding B9 (folic acid) and B12 to antipsychotics, but only in those with a specific genotype ([@bib133]). B6 improved extrapyramidal adverse effects of antipsychotics (TD and neuroleptic induced akathisia) in four (from four) studies ([@bib101], [@bib100], [@bib98], [@bib99]; [@bib114]). In one study on B3 in 57 children without antipsychotics, cognition and general psychopathology had not improved after 6 months ([@bib57]). Most B vitamins induced modest adverse effects, especially skin flushing and abnormal liver function induced by vitamin B3 and B6.

### (v) Antioxidants

Two RCTs on vitamin C were found ([@bib15]; [@bib27]). One reported improved general psychopathology and reduced adverse effects (reduced serum malondialdehyde; a lipid peroxidation product) when added to olanzapine (10 mg), quetiapine (200 mg), or ziprasidone (40 mg) after 8 weeks ([@bib27]). One study without antipsychotics found no effect on cognition or motor functioning after 10 days ([@bib15]). Both studies reported no adverse effects of vitamin C.

Four studies on ginkgo biloba were found ([@bib178], [@bib179], [@bib177], [@bib180]; [@bib181]). Three (from four) studies found improved positive symptoms ([@bib178], [@bib179], [@bib180], [@bib180]; [@bib181]), two (from three) found improved general psychopathology ([@bib178]; [@bib181]), and four (from four) reported no improvement of negative symptoms when added to antipsychotics ([@bib178], [@bib179], [@bib177], [@bib176]; [@bib181]). In all four studies, adverse effects of antipsychotics improved (behavioral toxicity, symtoms of nervous system, and TD). No adverse effects of ginkgo were reported.

Thirteen studies of vitamin E were found ([@bib1], [@bib2]; [@bib5]; [@bib26]; [@bib32], [@bib33]; [@bib36]; [@bib38]; [@bib92]; [@bib106]; [@bib137]; [@bib138]; [@bib141]). Six (from 13) studies for reducing EPSs, while using antipsychotics, showed a decrease of TD ([@bib1]; [@bib5]; [@bib26]; [@bib36]; [@bib38]; [@bib106]) and EPS (one study; [@bib38]), and those with shorter duration of TD seemed to improve more; no adverse effects of vitamin E were reported, except mild diarrhea in two studies. Five (from five) reported no effect on general psychopathology ([@bib2]; [@bib32]; [@bib38]; [@bib92]; [@bib106]). One study of melatonin for TD reported a decrease of TD and no adverse effects ([@bib140]).

### (vi) Other Substances

Agents that did not fit in the five aforementioned categories were classified in this residual category. A total of 16 high-quality RCTs have been performed on multivitamins ([@bib6]; [@bib165]), hormones (DHEA; [@bib117]; [@bib131]; [@bib132]; [@bib147], [@bib148]), pregnenolone (PREG; [@bib131]), estradiol ([@bib4]; [@bib88], [@bib89]), protilerin (thyrotropin-releasing hormone) ([@bib128]), testosterone ([@bib85]), inositol ([@bib103]), gamma-hydroxybutyrate (GHB; [@bib105]; [@bib139]) and des-tyr-gamma-endorphin ([@bib166]).

Two (from five) studies on DHEA added to antipsychotics showed improvement of negative symptoms ([@bib132]; [@bib147]), two (from three) on positive symptoms ([@bib131]; [@bib132]), one (from three) on cognition ([@bib132]), two (from two) on depression ([@bib132]; [@bib147]), and one (from four) on general functioning ([@bib147]). Three (from four) improved adverse effects of drugs ([@bib117]; [@bib131]; [@bib148]). In one study of 30 patients with schizophrenia, using either 5 g of 1% testosterone gel or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks, negative symptoms improved without adverse effects ([@bib85]). One (from one) small study (*N* = 12) on protilerin found improved general psychopathology ([@bib128]). Three (from three) studies on estradiol showed improvement of general psychopathology ([@bib4]; [@bib88], [@bib89]), two (from three) of positive symptoms ([@bib4]; [@bib88]), one (from one) of improved cognition ([@bib88]), and none (from three) of negative symptoms.

One (from one) small study (*N* = 14) on inositol found no effect on positive or negative symptoms ([@bib103]). Two (from two) studies on GHB found no improvement of general psychopathology ([@bib105]; [@bib139]). One (from one) very small (*N* = 6) study on des-tyr-gamma-endorphin found improvement on general psychopathology and positive symptoms ([@bib166]). No serious adverse effects of these agents were reported.

One study (of two) on artemisinin (a natural medicine against malaria) found a significant effect on negative symptoms and clinical global impression, but no effect on positive or cognitive symptoms or on general psychopathology in first-episode treatment-naive patients that were treated with risperidone ([@bib31]; [@bib168]). The study of [@bib31] did not demonstrate clinical benefit of adjunctive artemisinin for schizophrenia symptoms.

DISCUSSION
==========

This review describes the effects of natural agents in the treatment of psychotic disorders and of undesired effects of antipsychotics. Some studies suggest that glycine, sarcosine, NAC, several Chinese and ayurvedic herbs, ginkgo biloba, estradiol, and vitamin B6 may be effective for psychotic symptoms when added to antipsychotics (glycine not when added to clozapine). We found inconclusive or no evidence for omega-3 fatty acids, [d]{.smallcaps}-serine, [d]{.smallcaps}-alanine, [d]{.smallcaps}-cycloserine, other B vitamins, vitamin C, DHEA, PREG, inositol, GHB, and des-tyr-gamma-endorphin when added to antipsychotics. Reserpine without antipsychotics seemed effective in one old study but was poorly tolerated. Ayurvedic herbs seemed equally effective as olanzapine in only one study. Other agents as monotherapy (vitamin B3, vitamin C, sarcosine, glycine, and protilerin) were not effective or had only been tested in single or small trials. For alleviation of adverse effects, ginkgo and vitamin B6 seemed effective for TD and neuroleptic induced akathisia (NIA). The evidence for reducing some adverse effects of antipsychotics by omega-3 fatty acids, melatonin, and DHEA was inconclusive.

Apart from reserpine, all natural compounds studied caused no or mild undesired adverse effects. There is inconclusive evidence for improved outcome by combining omega-3 fatty acids with antipsychotics in schizophrenia. Earlier reviews reported similar conclusions ([@bib16]; [@bib75]; [@bib159]). A meta-analysis of randomized placebo controlled trails showed a modest, nonsignificant, beneficial effect of fatty acids in schizophrenia ([@bib50]).

Glycine and sarcosine combined with antipsychotics may reduce negative symptoms, but not when combined with clozapine and neither as monotherapy. Inconclusive evidence was found for [d]{.smallcaps}-cycloserine and [d]{.smallcaps}-serine on clinical improvement. Our results concur with two reviews ([@bib142]; [@bib156]) and are in line with a Cochrane review ([@bib151]). Conflicting results from studies on drugs targeting the glutamate/NMDA system may be explained by complicated dose-effect relationships, as recently found in studies with the GlyT-1 transporter antagonist bitopertin ([@bib160]).

By adding Chinese or ayurvedic herbs to antipsychotics, general psychopathology may improve. One study (of two) on artemisinin (a natural medicine against malaria) found a significant effect on negative symptoms and clinical global impression, but no effect on positive or cognitive symptoms or on general psychopathology in first-episode treatment-naive patients who were treated with risperidone ([@bib168]; [@bib31]). The study of [@bib31] did not demonstrate clinical benefit of adjunctive artemisinin for schizophrenia symptoms. [@bib130] state that "the results suggest that combining Chinese herbal medicine with antipsychotics is beneficial." Another Cochrane review ([@bib3]) concludes that "ayurvedic medication may have some effects for treatment of schizophrenia, but has been evaluated only in a few small pioneering trials." These results need further exploration and pharmacological differentation, as Chinese and ayurvedic herbs include hundreds of species combined in thousands of different combinations and are prescribed in a fundamentally different way than Western medicines ([@bib24]; [@bib82]). The combined approach using knowledge from both conventional and Chinese medicine seems promising, as it may lead to innovation ([@bib163]) and possibly to improved outcomes ([@bib180]).

Inconsistent beneficial outcomes of studies on B vitamins were identified, especially when given as a combination of B1, B3, B6, B9, and/or B12 with antipsychotics. One review concluded that no adequate support for the efficacy of B vitamins in schizophrenia can be identified ([@bib83]). Most studies with positive effects in our review, however, were published after the aforementioned review was published. Most convincing evidence was found for vitamin B6 added to antipsychotics, shown to be effective in diminishing general psychopathology and TD.

The findings on the efficacy of vitamin C for schizophrenia in only two RCTs were inconsistent, hindering definite conclusions. The efficacy of vitamin E on TD remains inconclusive, as only half of the included studies found some positive results. Even so, a meta-analysis by [@bib16] claimed, "Vitamin E could potentially improve TD." This may be due to the finding that those with a short history of TD tend to improve more than those with a longer history of TD. A Cochrane review in 2011 ([@bib144]) came to a similar conclusion: "small trials of limited quality suggest that vitamin E may protect against deterioration of TD. There is no evidence that vitamin E improves symptoms of this problematic and disfiguring condition once established."

Ginkgo biloba seems to benefit patients with schizophrenia in several ways when added to antipsychotics. Several studies suggested evidence for improving symptoms in various domains, especially an effect on positive symptoms and the reduction of adverse effects of antipsychotics.

On melatonin, one study provided preliminary evidence for diminishing TD ([@bib140]). As TD is difficult to investigate because of the fluctuating symptom severity, this study needs replication.

Some inconsistent evidence was found on improved outcomes by several hormones (DHEA, PREG, and testosterone) in schizophrenia, not allowing final conclusions. A Cochrane review on DHEA/testosterone drew a similar conclusion ([@bib37]). For estradiol, a Cochrane review reported no convincing evidence over placebo ([@bib23]). Since then, two studies found that estradiol improves positive (but not negative) symptoms and general psychopathology in schizophrenia when added to antipsychotics ([@bib88], [@bib89]), however only in women of childbearing age. Therefore, using estradiol in schizophrenia warrants further study.

Limitations
-----------

There are several methodological limitations. First, the wide scope of this review allows only general descriptions of included studies in six domains. Second, it is unclear to which extent our findings are influenced by publication bias, in favor of publication of studies with positive results. Third, we used the Jadad score to select only RCTs of high quality (with a score of three or higher, as is in accordance with other reviews \[*e.g.*, see [@bib150]\]). However, the Jadad score is not a perfect tool because it does not judge the selection of subjects, the sample size and power, and the quality of the data analyses. Therefore, RCTs with a Jadad score of 3 or higher might still have methodological weaknesses, which hamper drawing firm conclusions. Fourth, some studies (*e.g.*, [@bib15]; [@bib57]; [@bib118]) were done in the pre--*Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition* (*DSM-3*) era, when standards of care and diagnostics may have been of lower quality than nowadays, which hampers interpretation of their results. Fifth, in most of the studies included, effect sizes were not provided nor was it possible to calculate them, which makes it difficult to compare the results or to estimate the clinical relevance of some of the findings. Sixth, it cannot be ruled out that some of the studies were underpowered, which might have hampered finding a significant effect.

Clinical Implications
---------------------

Clinicians need to be aware that patients often use natural medicines without medical prescription, whereas some patients assume that natural is better than chemical and causes fewer adverse effects. Although beneficial effects may occur, this is certainly not always true. Some natural agents that may be suggested for treatment of psychotic disorders are toxic to humans ([@bib153]), and some herbal medicines can cause adverse effects or interact with medication ([@bib45]). Only 3% of the user population is aware of the potential risks of interactions between herbs and prescription medication ([@bib167]). From a medical perspective, it is therefore important to know what patients buy and try. Another concern are the media reports on contamination of Chinese herbs with heavy metals. However, after investigation of 334 samples, [@bib58] conclude that "the vast majority (95%) of medications in this study contained levels of heavy metals or pesticides that would be of negligible concern." Because of these concerns, patients want their medical doctors to advise them on complementary (or natural) medicines ([@bib56]; [@bib68]). [@bib172] has repeatedly advised its member states to "formulate national policy and regulation for the proper use of CAM and its integration into national health care systems; establish regulatory mechanisms to control the safety and quality of products and of CAM practice; create awareness about safe and effective CAM therapies among the public and consumers" and "promote therapeutically sound use of appropriate Traditional Medicine by practitioners and consumers." Respecting patients\' opinions and informing them may also improve the therapeutic relationship ([@bib146]) and thus enhance treatment outcome ([@bib51]; [@bib86]), which depends on the quality of the therapeutic alliance ([@bib9]).

This review gives clinicians and patients an overview of the results of RCTs, which fit a minimal level of quality (minimum Jadad score of 3), on the efficacy and safety of natural medicines for psychotic disorders. However, many questions about clinical use (*e.g.*, dosage, safety, interactions, and quality) remain unanswered.
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